INmune Bio, Inc.INMBNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | -100.00% | +257.14% | +0.00% | +0.00% |
| Gross Profit Growth | -100.00% | -100.00% | +257.14% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +12.09% | +24.12% | +24.80% | +20.67% | +31.70% |
| Weighted Average Shares Diluted Growth | +12.09% | +24.12% | +24.80% | +20.67% | +31.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -37.25% | -42.30% | -47.36% | -36.86% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -15.82% | -30.59% | -19.29% | -28.16% | -36.80% |
| Book Value per Share Growth | -22.87% | -32.19% | -18.08% | -35.49% | -50.18% |
| Debt Growth | -77.44% | -96.32% | -95.63% | -91.70% | -62.92% |
| R&D Expense Growth | +68.20% | +22.41% | -12.12% | -17.71% | -51.46% |
| SG&A Expenses Growth | -14.19% | -11.92% | -0.94% | -19.88% | +13.47% |